As part of the French delegation, alongside Business France Healthcare North America, ETAP‑LAB will take part in BIO Partnering™, the reference platform for one‑to‑one business meetings during the event.

👉 Learn more about the event: https://convention.bio.org/

Where innovation meets decision-making

The BIO International Convention is not just a scientific conference — it is where strategic decisions are made.

Over four days, biotech startups, pharma leaders, CROs, and investors gather to:

• initiate partnerships
• accelerate R&D programs
• secure funding and licensing deals
• move innovative therapies toward patients

For companies navigating the complexity of drug development, BIO is a unique opportunity to connect directly with the right partners at the right time. Meet ETAP-LAB this time!

Why meet ETAP‑LAB at BIO 2026?

At ETAP‑LAB, our objective at BIO is clear: help you move your therapeutic innovations forward with confidence.

We support all types of preclinical-stage projects, from early discovery to advanced translational studies, including  in vitro lead optimization to non-GLP animal testing (POC studies, PK/PD modeling and non-regulatory safety pharmacology).

Whatever your range of therapeutic innovation: small molecules, antibodies & biotherapies, cell therapies, medical devices and nutraceuticals.

What you gain by meeting us

Whether you are:

• preparing an IND
• validating a candidate before fundraising
• or facing key go/no‑go decisions

We provide advice and expert services:

• robust, decision‑enabling data with high translational relevance
• optimized study designs to reduce experimental and regulatory risks
• fast, responsive support adapted to your timelines
• end-to-end capabilities, from in vitro to in vivo and advanced analyses

From early discovery to in vivo validation: a fully integrated approach

One of ETAP‑LAB’s key strengths lies in its transversal expertise.

For example, in neurodegenerative diseases such as Alzheimer’s:

• start with high‑content in vitro screening (human iPSC-derived models, primary cells)
• refine candidate selection with multiparametric analyses
• progress seamlessly toward in vivo studies, including advanced behavioral pharmacology
• complete your program with integrated biological analyses (e.g. immunohistochemistry)

Result: A consistent, reliable data package to support your development milestones and investor discussions.

New structure, clearer offer: discover our 4 specialized brands

BIO 2026 will also be the opportunity to introduce our new brand architecture and website.

To improve clarity and enhance your experience, we have organized our expertise into four dedicated service brands:

• BRAINXPLORE — Neurology / CNS
• SKINAXIS — Dermatology
• STROK@LLIANCE — Neurovascular / Stroke
• SYNCROSOME — Cardiology

All under one unified entity, ETAP‑LAB, as a trusted & renowned preclinical CRO.

What’s new for you

• clearer service positioning by therapeutic area
• easier navigation across our portfolio of models and technologies
• faster access to expert teams
• a more intuitive and efficient customer journey

Explore our new website now: https://www.etap-lab.com/en/

Meet us through BIO Partnering™

ETAP‑LAB will be available exclusively through BIO Partnering™ one‑to‑one meetings, and also at the French Pavilion.

👤 Nicolas Violle, CEO, will be on-site to discuss your projects.

You should meet us if you have an ongoing preclinical program and need a trusted CRO partner with strong scientific expertise.

📅 Request a meeting directly via the partnering platform (https://convention.bio.org/) or through our website (https://www.etap-lab.com/en/contact/).

Supported by our ecosystem

ETAP‑LAB’s participation in BIO 2026 is supported by:

• Eurobiomed, through its international development program, and the Région Sud Provence-Alpes-Côte d’Azur, providing financial support.
• Business France Healthcare North America, as part of the French delegation

This backing reflects the recognition of ETAP‑LAB’s expertise and its ambition to expand internationally.

Let’s accelerate your preclinical development

At BIO 2026, our goal is simple: help you reduce uncertainty, gain clarity, and move faster toward clinical development.  We look forward to meeting you in San Diego.

In the meantime, feel free to subscribe to our NEW newsletter, which will be released in June 2026!

L’article BIO Convention 2026: meet ETAP‑LAB in San Diego est apparu en premier sur ETAP-LAB.

On this occasion, Nicolas Violle, CEO of ETAP‑LAB, will be attending to meet early‑stage biotech, pharma, and medtech companies and discuss the scientific and strategic challenges of preclinical drug development.

👉 Learn more about the event:
🔗 https://www.swissbiotech.org/event/swiss-biotech-day/

A key meeting point for the international biotech ecosystem

Bringing together several thousand participants from around the world, Swiss Biotech Day has become a major hub for innovation and partnering. The event fosters concrete discussions, scientific collaborations, and international partnerships among project leaders, CROs/CDMOs, industrial players, and investors, all focused on advancing innovative therapeutic programs toward the clinic.

For ETAP‑LAB, participation in Swiss Biotech Day is driven by a clear business objective: connect with project teams, understand their R&D challenges, and propose tailored preclinical support at critical stages of development.

Preclinical expertise dedicated to ambitious programs

ETAP‑LAB is an independent CRO with recognized expertise in in vitro and in vivo preclinical pharmacology, particularly in the fields of:

• Dermatology
• Cardiology
• Neurology, including CNS and stroke (ischemic and hemorrhagic)

Our mission is to support and accelerate drug candidate development by providing robust, translational models that generate reliable, decision‑enabling data throughout the preclinical phase.

A trusted partner built on rigor and proximity

With more than 35 years of experience, ETAP‑LAB is distinguished by:

• a high level of scientific rigor,
• full transparency throughout each project,
• strong responsiveness,
• and a close, collaborative client relationship, essential for building efficient and long‑term partnerships.

Meeting ETAP‑LAB at Swiss Biotech Day means engaging with a committed partner able to secure and streamline your preclinical development strategy.

📅 Schedule a meeting with ETAP‑LAB

ETAP‑LAB is registered on the official Swiss Biotech Day partnering platform.
👉 We invite you to book a one‑to‑one meeting with Nicolas Violle to discuss your projects and R&D challenges directly.

➡️ Schedule your meeting via the event’s partnering platform and meet us in Basel to move your preclinical programs forward together.

L’article Swiss Biotech Day 2026: accelerating preclinical development together est apparu en premier sur ETAP-LAB.

We look forward to seeing you at this world’s largest neuroscience conference, organized by the Society for Neuroscience (SFN), with high-quality programming for scientists from around the world.

📅 When to meet our scientists

ETAP-Lab will unveil two scientific posters on original preclinical results:

Nicolas Violle, CEO and expert in Neuroscience, will present the latest results from our Neuroscience Lab with poster No. PSTR066.10 – “High-throughput brain-on-chip platform for accelerating neurodegenerative drug discovery”.
Session date and time: November 16, 2025, 8:00 AM – 12:00 PM.

Research in partnership with NETRI on the BIO-DIAMOND* program.

REQUEST THE POSTER

Annelise Letourneur, Preclinical Director at STROK@LLIANCE lab, will present the exclusive results of studies conducted for a client, including the successive preclinical stages at STROK@LLIANCE in the development of its stroke drug candidate, with poster No. PSTR443 – “A Translational Multi Model Platform for Preclinical Evaluation of Thrombolytics in Acute Ischemic Stroke”.
Session date and time: Wednesday, November 19, 2025, 1:00 PM – 5:00 PM.

REQUEST THE POSTER

📍 Where to find us

For the first time, we will welcome you at booth #534, with our expert teams ready to advise, as well as Sandra Robelet, our Business Developer.

You will also have the opportunity to meet our new American partner, GEN2X, based in San Diego. We have big surprises in store at our booth, so come and visit us.

🧠 Our models, designed to meet your challenges

We understand the challenges involved in your research to develop your drug candidates.

Do you want to optimize the development of your neurological drugs through translational preclinical studies? Do you need to know how to test the efficacy of your drug candidates? Do you need to reproduce the pathological characteristics of degenerative neurological disorders?

Our teams are committed to providing you with the best advice, quality services, and translational models to facilitate your transition to the next stages, all the way to clinical trials.

SCHEDULE AN APPOINTMENT – WELCOME TO OUR BOOTH #534

More to discover:
Have a look at our range of models and readouts in Neurovascular & Neurology fields.
Register for the congress: Sessions and Events
BIO-DIAMOND program advances here: https://netri.com/biodiamond/

Even more to discover when coming to visit us

We offer efficacy, drug interaction and non-regulatory safety studies in the fields of neurovascular and neurological diseases. Our neuroscience offering relies on a broad portfolio of in vitro to in vivo efficacy models for neurodegenerative diseases (proteinopathies, AD, PD and more), psychopharmacology (motor, mood and learning disorders), as well as ischemic and hemorrhagic strokes. We also offer novel in vitro Brain-on-Chip models.

BIO-DIAMOND program*: a collaborative project with NETRI aiming to accelerate the time-to-market of drug candidates in the discovery and preclinical phases for Alzheimer’s disease and other neurodegenerative diseases. Winner of the “Innovations in biotherapies and bioproduction” call for projects, financed by the French government as part of France 2030.

L’article SfN NEUROSCIENCE 2025 – Empower your drug candidates with our translational preclinical models est apparu en premier sur ETAP-LAB.

L’article Pitch at the TECNIPLAST Scientific Symposium France 2025 est apparu en premier sur ETAP-LAB.

🔗 Learn more about the ESDR Meeting

Meet our team at Booth #2

Our team will be pleased to present our offer of preclinical dermatological models in skin inflammation, wound healing as well as skin grafting.

Schedule a meeting now with Jean-François Bisson, PhD, Director of Studies, and Jérôme Bernard, Chief Business Officer, by contacting us.

I want to schedule a meeting

Poster session – spotlight on our ischemic skin wound model

Don’t miss our scientific poster (#518), presented by Jean-François Bisson, highlighting the results of a client study on ischemic skin wounds, conducted in collaboration with École Polytechnique, Laboratoire de Physique des Plasmas and Plasana Médical.

This study contributed to the preclinical development of the Plasana One® technology, an innovative device now entering clinical trials, designed to efficiently treat chronic wounds such as venous leg ulcers and diabetic foot ulcers.

Poster title: “Pro-healing effects of Plasana One®, an argon-generated cold plasma on ischemic skin wounds”
Poster available for download after the conference.

REQUEST THE POSTER NOW

From gold standard models to tailored solutions for your specific dermatology projects

At ETAP-Lab, a French preclinical CRO for over 30 years, we offer in vivo preclinical research services in the dermatology field.

Leveraging our gold standard models and tailor-made solutions, we support your molecule development across areas such as psoriasis, atopic dermatitis, wound healing and skin grafting, using our platforms (microsurgery, stereotaxy, behavior, bioassays, (immuno)histology and more).

Explore our full range of dermatological models.

Event details:
📅 When: September 10–13, 2025
📌 Where: Flanders Meeting & Convention Center Antwerp – “A Room with a Zoo”
Address: Koningin Astridplein 20–26, 2018 Antwerp, Belgium
🎫 Register: https://esdrmeeting.org/registration/

We look forward to discussing your thoughts and exploring potential collaborations.

About Plasana Médical:

Plasana Médical was created by Yves Matton, from the startup studio Technofounders, and Professor Antoine Rousseau, Research Director at the Plasma Physics Laboratory (LPP) at École Polytechnique.

The company was founded in 2022, after more than 10 years of research on plasma medicine at LPP and following initial successful preclinical trials demonstrating the beneficial effects of cold plasma on wound healing.

This new type of treatment accelerates healing time and limits infections thanks to the antiseptic effect of cold plasma. Plasana Médical’s mission is to bring this technology to market to improve patients’ quality of life, facilitate the work of healthcare professionals, and reduce healthcare costs.

L’article ESDR Meeting 2025 – Rediscover Our Preclinical Dermatology Expertise est apparu en premier sur ETAP-LAB.

ETAP-Lab will be present at the AFSSI Connexions 2025 in Toulouse on July 1 and 2 to present the poster resulting from the research work of the laboratory dedicated to Neurology and Neurodegenerative Diseases.

Healthcare R&D and Innovation: French preclinical CROs at the heart of European leadership

AFSSI (the French Association of Service and Innovation Companies), in partnership with AD’OCC, the Occitanie region’s economic development agency, is organizing the 12ᵉ edition of AFSSI Connexions on July 1 and 2, 2025 in Toulouse. This annual event brings together key players in preclinical research and healthcare innovation for two days dedicated to exchanges and the creation of synergies.

🧠 We’ll be there to meet you, and Sandra Robelet will be presenting the poster “Advancing Alzheimer’s disease (AD’s) models for preclinical drug testing”*, which continues the work presented in 2024, demonstrating how we can screen the next generation of AD treatments thanks to in vitro models, combining neuron and glia, using Brain-on-Chip devices and targeting both amyloid and tau.

Join us for this 12ᵉ edition of AFSSI Connexions, moments of exchange and sharing. It’s an opportunity to discover our preclinical skills, know-how and innovations essential to Life Sciences players.

Contact us to receive the PDF poster or for a meeting!

Contact us

This year’s key themes:
The growth challenges facing the French preclinical CRO sector
The liability stakes relating to the use of animals for scientific purposes

Find out more about the program and register!

*About the poster:
A part of this project is co-financed by the Region Grand-Est and the European Union through the FEDER-FSE Lorraine and Massif des Vosges 2021-2027 operational program.
BIO-DIAMOND project, NETRI and ETAP-Lab industrial consortium, is funded by the French government as part of the France 2030 call for proposals “Innovations in biotherapies & bioproduction”.

L’article Neurology poster at the AFSSI Connexions 2025 est apparu en premier sur ETAP-LAB.

ETAP-Lab will be presenting a poster during the next edition of the SPIN 2025 Congress, organized every 3 years by the René Touraine Foundation, focused on Skin Inflammation & Psoriasis diseases.

Let’s talk inflammation at SPIN with our poster on our reference models using our unique translational approach focused on assessing rodent behavior and well-being. We share an overview of over 10 years of study results, showing just how reproducible and significant our findings are.

If you are interested in our latest insights on Psoriasis & Atopic Dermatitis, you can join our team!

Jean-François BISSON, PhD, Study Director of our preclinical dermatology laboratory, and Lianna RAZAFITRIMO, in vivo Preclinical Project manager, present the poster on “Behavioural assessment as a tool for evaluation of efficacy therapies associated with well-being recovery in preclinical models of skin diseases”.

About the congress:
At the International Conference of SPIN Skin Inflammation & Psoriasis International Network
In Paris – from July 2 to 4
Poster Walks – at Foyer Moebius – Thursday, July 3, 12:00–13:00

As a preclinical expert in skin diseases for over 20 years, ETAP-Lab is committed to remaining at the forefront of dermatological science. We look forward to discussing your thoughts and exploring potential collaborations.

ASK FOR A MEETING

Request our PDF poster when available!

L’article Preclinical Dermatology – Discover our Poster at SPIN 2025 Congress in Paris est apparu en premier sur ETAP-LAB.

Meet our expert during the poster session

L’article Neurodegenerative diseases & microfluidic platform – Poster session at the MPS World Summit in Brussels est apparu en premier sur ETAP-LAB.

Want to know more about our preclinical expertise and services?

Meeting request or Request our Portfolio of models

JNBB | National Biomedicines Manufacturing Day
June 5, 2025 | ORAL & BOOTH | Nancy, France.
Organized with MTInov, ENSAIA, BioValley France & France BioLead

About the event: https://www.france-biolead.fr/en/content/jnbb2024

MPS Microphysiology Systems World Summit
June 9 – 13, 2025 | POSTER | Brussels, Belgium.
Organized with EUROoCS
About the event: https://mpsworldsummit.org/

Bio Convention US
June 16 – 19, 2025 | BtoB PARTNERING & BOOTH #1935 | Boston, USA.
Organized with Eurobiomed & Biotechnology Innovation Organization
About the event: https://convention.bio.org/bio-2025

AFSSI Connexions
Juy 1 – 2, 2025 | POSTER & BtoB MEETING | Toulouse, France
Organized with AFSSI Sciences de la Vie
About the event: https://www.afssi-connexions.fr/

SPIN | Congress of the Skin Inflammation & Psoriasis International Network
July 2 – 4, 2025 | POSTER | Paris, France
Organized with Fondation René Touraine
About the event: https://spincongress.org/synoptic-program/

L’article Upcoming events to meet our experts across Europe & US est apparu en premier sur ETAP-LAB.

When: from May, 15th to 17th.
Where: on Campus Belval, at University of Luxembourg, in Luxembourg.
Poster session: POSTER #2 on May, 15th

🧑‍🔬 Meet our expert during the poster session
Dr Ahmad Allouche, Head of in vitro Biology, will be presenting the poster on “Neuroinflammation Models of Neurodegenerative Diseases”.
Let’s meet there to explore our in vitro & in vivo services dedicated to AD’s & PD’s translational neuroscience, especially focused on proteinopathies & other neuronal injuries.

🧠 At ETAP-Lab we support biotech & pharmaceutical companies to accelerate the development of transformative neurodegenerative therapies, aiming at a better future for all those affected by neurodegenerative diseases.

You can connect with us for a meeting or for more details on our models portfolio:

ASK FOR A MEETING

 🔬If you are not going to this event, don’t hesisate to request our PDF poster when available!

Focus on the 8th edition:
As one of the major international events on Neuroinflammation, this meeting will focus on the theme “Cerebral immune activation at the crossroads of healthy aging, senescence and neurodegeneration” encompassing basic, clinical, methodological and emerging perspectives and including internationally renowned scientists with expertise across a wide range of domains, as main speakers.
The conference offers new grounds for scientific exchange, joint strategies and collaborative actions within the Neuroinflammation community on an international level.
More about the scientific programme: https://neuroinflammation.uni.lu/programme/

L’article Neuroinflammation – Poster session at the Venusberg Meeting in Luxembourg est apparu en premier sur ETAP-LAB.

Come & discover the company during a presentation of ETAP-Lab’s activities in preclinical research for innovation in healthcare.

And meet our recruiters all afternoon for a jobdating!
Pascale ROZAN and Tyffanie PILLER will be on stand all day at the Animalerie Pédagogique – Agrocampus des 2 Vallées in Vendôme.

L’article LABDATING in Vendôme – Always on the lookout for future talent! est apparu en premier sur ETAP-LAB.

L’article See you at SKIN SUMMIT in France est apparu en premier sur ETAP-LAB.

L’article Visit our booth & poster at AD/PD 2025 conference in April est apparu en premier sur ETAP-LAB.

• Novel targets beyond Aβ
• Deciphering disease complexity
• Enhancing α-synuclein detection
• Advancing blood-based biomarkers

L’article Let’s meet at AD’s & PD’s Drug Development Summit in Boston! est apparu en premier sur ETAP-LAB.

ETAP-Lab’s team is looking forward to attending this global event that explores “the forefront of stroke and cerebrovascular disease topics and present the most influential late breaking clinical trials”.

As a preclinical efficacy CRO, ETAP-Lab will unveil its poster on original preclinical results about in vivo assays on Stroke disease.

The results presented have been possible also thanks to STROKTURA* program.

📅Join our expert during the poster session

Annelise LETOURNEUR, Director of Operations at STROK@LLIANCE and Neuroscience Study Director, will present the poster

“Translational models of hemorrhagic transformation to evaluate the safety of new therapies in acute stroke: effects of age and hypertension in diabetic mice“.

Session details:

• Session Name: 0460 – SHORT COMMUNICATIONS 02: BASIC SCIENCE AND TRANSLATIONAL RESEARCH & DATA SCIENCES AND ARTIFICIAL INTELLIGENCE (ID 1584)
• Date : Wed, 23.10.2024
• Session Time: 14:00 – 15:30
• Room: Hall G
• Lecture Time: 14:56 – 15:00

🧠Our specific stroke models, reproducing translational challenges.

Would you like to support the development of your neurological drugs with preclinical studies? Do you need to test the efficacy of your molecules in translational models that mimic different commorbidity parameters?

Thanks to our robust expertise in preclinical neurology, we can advise with relevant and translatable range of stroke models from in vitro to in vivo. Our key innovation is to offer models in optimal translational situations that combine stroke with metabolic diseases, diabetes or aging.

More to discover:

• Have a look at our wide range of models in Neurology field and especially in stroke!

• You can connect with us at marketing@etap-lab.com and ask for the posters in PDF.

*About STROKTURA

STROKTURA, Stroke for the Future, aims to find innovative solutions in brain imaging applied to preclinical models of stroke, with the purpose of testing future therapies for ischemic strokes in humans. This project, led by our team of experts in collaboration with BB@C, with scientific and technical support from PhIND, ESR3P, and CYCERON, is financially supported by FEDER and the Normandy Region.

L’article Join us at the 16th World Stroke Congress in Abu Dhabi this October! est apparu en premier sur ETAP-LAB.

That meeting is the World’s Largest Neuroscience Conference, organized by the Society For Neuroscience (SFN), and with an exciting programming for the scientists coming from around the world!

ETAP-Lab will unveil two posters on original preclinical results about in vitro and in vivo assays on Alzheimer’s disease.

📅Let’s meet our scientists during the poster sessions

• Nicolas Violle, CEO and expert in neuroscience, will present the poster #PSTR013.14 – Towards new relevant neuroinflammation models using oligomers involved in Alzheimer’s disease for target validation and drug testing. Poster presentation on Day 1 Sat., Oct. 5, 2024 from 2 p.m. to 3 p.m.

• Julie Colin, Preclinical Project Manager in Neuroscience, will present collaborative results with our partner NETRI, also exhibiting in the congress – with the poster #PSTR387.08 – Brain-on-chip technology and high-content analysis system to improve and accelerate preclinical Alzheimer’s disease drug research. Poster presentation on  last Day, Wed., Oct. 9, 2024 from 11 a.m. to noon

🧠Our Neurological models, tailored to your challenges.

Would you like to empower your neurological drug development through preclinical studies ? You need to know how to test the efficacy of your molecules and your proof of concept?  You need to mimic the pathological features of NDD’s?

At ETAP-Lab we can advise with our relevant and translatable in vitro and in vivo models. We have developed a wide range of neurodegenerative diseases models (Alzheimer and Parkinson), as well as stroke models​ and in vivo models of young & aged rodents​ in psychopharmacology!

We also propose novel in vitro Brain-on-chip models that are developed in BIO-DIAMOND Project, a collaborative project with NETRI aiming at accelerating the time-to-market of drug candidates in the “discovery” and “pre-clinical” phases in the fields of Alzheimer’s, Parkinson’s and Amyotrophic Lateral Sclerosis (ALS).

France 2030 supports “Innovations in biotherapies and bioproduction” by selecting the NETRI and ETAP-Lab industrial consortium. Winners of the “Innovations in biotherapies and bioproduction” call for projects, financed by the government as part of France 2030, NETRI and ETAP-Lab have launched their BIO-DIAMOND project in 2023.

More information about the project advances here: https://netri.com/biodiamond/

More to discover:

• Have a look at our wide range of models in Neurology field!

• You can connect with us at marketing@etap-lab.com and ask for the posters in PDF.
• Discover the congress: https://www.sfn.org/meetings/neuroscience-2024

L’article Discover our latest NDD’s results at the NEUROSCIENCE 2024 in Chicago est apparu en premier sur ETAP-LAB.

We are delighted to participate for the first time to Nordic Life Science Days, the largest Nordic partnering conference dedicated to the life science industry.

🎯 Explore our wide range of services, from gold-standard to tailored models designed to tackle your challenges
You look forward accelerating & derisking the development of your drugs and/or medical devices in Dermatology, Neurology, or Cardiology thanks to preclinical efficacy studies ?
At ETAP-Lab – French preclinical CRO for over 30 years – we support your preclinical development thanks to relevant & translatable in vivo and in vitro models implemented by our research team !
You can have a look at our wide range of models in our website !

📆 Let’s discuss your challenging issues
Our Business Developer is ready to advise on your specific needs. Just ask for a meeting with Jérôme Bernard during NLSDays One-on-One Partnering:
– Directly through the NLSD online portal 
– You can’t join us ? You can also request a virtual appointment with our expert to tell us about your needs

Looking forward to connect with your company !

L’article Meet ETAP-Lab at NLSDays 2024 for Partnering Opportunities est apparu en premier sur ETAP-LAB.

FENS Forum 2024, taking place in Vienna this year, is organized by the Federation of European Neuroscience Societies (FENS), the Austrian Neuroscience Association (ANA) and the Hungarian Neuroscience Society. The FENS Forum is Europe’s largest neuroscience congress, covering all areas of neuroscience from basic to translational research. It will feature an exciting programme of plenary and special lectures, scientific symposia, technical workshops, special interest events, career development and networking opportunities and so much more!

🎯 Our broad offering, tailored to your challenges

You look forward accelerating the development of your drugs and/or medical devices in Neurology thanks to preclinical studies ?

At ETAP-Lab – French preclinical CRO for over 30 years – we can accelerate, derisk and support your preclinical development thanks to relevant & translatable in vitro and in vivo models !

We developped a wide offer of neurodegenerative diseases models (Alzheimer and Parkinson) from in vitro to in vivo, as well as stroke models​ and in vivo models of young & aged rodents​ in psychopharmacology.

📆 Let’s meet in our booth 1004

Our team would be happy to meet you during FENS Forum and present our portfolio of neurological models. Let’s arrange a meeting Booth 1004 by contacting us at marketing@etap-lab.com and see you in Vienna !

🌿 A “sustainably-designed” event

ETAP-Lab is proud to participate to a sustainably-designed event designed by FENS Federation and carried out  according to the Guideline of the Austrian Ecolabel for Green Meetings and Green Events. In this context, they aim to support sustainable consumption and production, trying to save resources, avoid waste, and act in an environmentally conscious way in all fields. All shell schemes provided by Standout – like ETAP-Lab’s – are reusable (aluminium system), with energy-saving lighting systems (LED lamps), carpets are reusable and recyclable.

More to discover:

• Have a look at our wide range of models !
• Check out some concrete sustainable actions implemented by FENS
• Discover FENS Forum 2024 in video: FENS Forum 2024: Welcome to Vienna!

L’article Meet ETAP-Lab at the FENS Forum 2024 – Booth 1004 est apparu en premier sur ETAP-LAB.

➡ETAP-Lab, represented by its CEO Nicolas Violle, will be taking part in the round table “France 2030: how to support excellence in the healthcare sector in the territories?“

This round table will be featuring Charles-Edouard Escurat from the Agence de l’Innovation en santé, Jean-Luc Dimarcq from the IHU Strasbourg, and moderated by Jean Sibilia.

👉 You can find the full programme with other round tables and pitches from the stakeholdes shaping tomorrow’s healthcare and register here: https://www.biovalley-france.com/fr/agenda/nextmed-day-rapprochons-le-futur-de-la-sante/

🤝 An event organised by BioValley France, Nextmed Strasbourg, SATT Conectus, the University Hospitals of Strasbourg, with the support of Quest For Health and other members of the local innovation ecosystem.

L’article Nextmed Day – ETAP-Lab taking part in a round table est apparu en premier sur ETAP-LAB.

This annual BIO International Convention, hosted by Biotechnology Innovation Organization (BIO), is the world’s largest industry gathering, bringing together thousands of global biotechnology and biopharmaceutical leaders.

🎯 Our broad offering, tailored to your challenges

You look forward accelerating the development of your drugs and/or medical devices in Dermatology, Neurology, Gastroenterology or Cardiology thanks to preclinical studies ?

At ETAP-Lab – French preclinical CRO for over 30 years – we can accelerate, derisk and support your preclinical development thanks to relevant & translatable in vivo and in vitro models !

📆 Let’s plan a meeting 

To determine how we could fit your specific needs, our Business Developers would be happy to meet you during BIO’s One-on-One Partnering™. Just ask for a meeting with Jérôme Bernard and/or Sandra Robelet:

• Directly through the online portal
• Can’t wait for it ? Or not enough time to meet there ? No worry, just contact us at marketing@etap-lab.com and let’s plan a call whenever you prefer.

🙏A supported French delegation

Thanks to the HealthCare innovation France 2030 plan, we are proud to participate to BIO International Convention in the French delegation made up with companies at the forefront of innovation. We send a warm thanks also to our French partners in this Business adventure: CCI International Grand Est, Business France Healthcare and Eurobiomed.

Looking forward to sustainably connect with counterparts in the U.S. and worldwide !

More to discover:

• Have a look at our wide range of models !

• Go to 2024 BIO International Convention
• Read our press release dated on 31th June, 2024

L’article ETAP-Lab to attend the 2024 BIO International Convention for Partnering Opportunities est apparu en premier sur ETAP-LAB.

Download the poster to learn more about his work !

A relevant model of thromboembolic stroke in diabetic mice for the preclinical evaluation of hemorrhagic transformation risk related to new therapeutic agents

L’article SfN 2022 – Poster est apparu en premier sur ETAP-LAB.

Florent Lebrun will share with you our last results concerning
“A relevant model of thromboembolic stroke in diabetic mice for the preclinical evaluation of hemorrhagic transformation risk related to new therapeutic agents” (Poster 287.19 – Abstract 5578 – Novermber 14th – Morning poster session).

We’d be delighted to meet you!

L’article Society for Neuroscience annual congress in San Diego (USA) – 12th to 16th november. est apparu en premier sur ETAP-LAB.

L’article Meet us at BIOEurope 2021! est apparu en premier sur ETAP-LAB.

L’article Meet us at BioEurope 2021! est apparu en premier sur ETAP-LAB.

Please feel free to contact us to schedule a video conference.
We’re hoping to meet you soon!

L’article Meet us at the World’s Largest Virtual Partnering Experience! est apparu en premier sur ETAP-LAB.

L’article Bio Digital: Meet us at the World’s Largest Virtual Partnering Experience! est apparu en premier sur ETAP-LAB.

We were able to show that the accelerated healing achieved by use of the innovative UrgoStart dressings was linked to faster and denser reconstruction of the local vascular network, in comparison with control conditions in rats. These results, invaluable for URGO laboratories, have made it possible to demonstrate histological modifications supporting the effects of UrgoStart.

Back in 2010, ETAP-Lab had already conducted the preclinical studies showing the beneficial effects of the UrgoStart dressing on healing. Continuation of this work in the clinical setting allowed URGO laboratories to win the Prix Galien 2018 in the Medical Device category.

For further information, please see the full poster here.

ETAP-Lab has been evaluating the effectiveness of medical devices on behalf of its dermatology clients for 20 years now.

Find out more

L’article EWMA: Presentation of the results of work we conducted for URGO laboratories est apparu en premier sur ETAP-LAB.

We will be at BIO Japan 2020 throughout, from 14 to 16 October. Our experts Dr. Jean-François Bisson (VP) and Dr. Nicolas Violle (CEO) will be there to introduce you to the laboratory’s activities in preclinical Neurology, Dermatology and Nutrition-Health.

Please feel free to contact us to schedule a video conference.

We’re hoping to meet you soon!

L’article BIO Japan 2020 est apparu en premier sur ETAP-LAB.

Thanks to everyone we met – we really appreciated the quality of our discussions, and are as excited as ever to be working alongside you on your #stroke #preclinical projects.

Thanks also to CCI France and Business France, for supporting the export of innovative French CROs and biotechs.

L’article B2B meetings at BIO-Digital est apparu en premier sur ETAP-LAB.

Thanks also to Business France and CCI France, for supporting the export of innovative French biotechs and CROs.

L’article B2B meetings at BIO-Digital: A fast-paced week filled with opportunities! est apparu en premier sur ETAP-LAB.

Please feel free to reach out if you want to schedule a one-to-one meeting. Looking forward to meeting with you.

L’article Meet us at BIO-Digital, 8-12 june est apparu en premier sur ETAP-LAB.

Please feel free to reach out if you want to schedule a one-to-one meeting. Looking forward to meeting with you.

L’article Meet us at BIO-Digital, 8-12 june est apparu en premier sur ETAP-LAB.

For the end of 2019, join us at the BioFIT event in Marseille, France

Syncrosome invites you to visit us at BioFit, December 10th to December 11th 2019, in Marseille, France.

Emmanuelle Bettendorf, our Business Developer, and Sandra Robelet our Scientific Manager, would be delighted to meet you their and discuss your in vivo preclinical projects.

We can give you advice about our in vivo efficacy, CNS-PK and PK services, discuss any in vitro or in vivo project requirements that you might have or just to get to know each other.

Please contact us to organize a 1-2-1 meeting in Marseille !

A few words about Syncrosome:

Syncrosome is an Efficacy Characterization CRO and we offer relevant disease models, cutting-edge techniques and a comprehensive background of physiopathology to assist drug discovery companies.

We have developped and validated so far more than 15 disease models, and our flexible and human-sized organization can design and operate tailored experimental protocols to give you appropriate answers.

Our main activities consit in :

• Drug Efficacy Studies in several therapeutic areas :
  • Central Nervous Sytem,
  • Cardiovascular and Metabolic disease,
  • Respiratory,
  • Gastroenterology.
• Early bioavailibility and CNS-PK on rodents and non-rodents with a high competence in the study of the Blood Brain Barrier passage.

L’article Biofit 2019, Marseille est apparu en premier sur ETAP-LAB.

Please feel free to contact us if you want to schedule a one-to-one meeting. Looking forward to meeting with you.

Contact us

L’article Meet us at BIO Europe in Hamburg, 11-13 November est apparu en premier sur ETAP-LAB.

Please feel free to contact us if you want to schedule a one-to-one meeting. Looking forward to meeting with you.

L’article Meet us at BIO Europe in Hamburg, 11-13 November est apparu en premier sur ETAP-LAB.

Emmanuelle Bettendorf, Account Manager in Syncrosome since 2009, will attend this international congress and will present the preclinical’s activities of Syncrosome to the 700 delegates coming from Biotech and Pharma environment.

A few words about Syncrosome: 

Syncrosome is an Efficacy Characterization CRO and we offer relevant disease models, cutting-edge techniques and a comprehensive background of physiopathology to assist drug discovery companies.

We have developped and validated so far more than 15 disease models, and our flexible and human-sized organization can design and operate tailored experimental protocols to give you appropriate answers.

Our main activities consit in :

• Drug Efficacy Studiesin several therapeutic areas :
  • Central Nervous Sytem, 
  • Cardiovascular and Metabolic disease, 
  • Respiratory,
  • Gastroenterology.

Early bioavailibility and CNS-PKon rodents and non-rodents with a high competence in the study of the Blood Brain Barrier passage.

L’article Syncrosome will attend the 19th Annual Biotech in Europe Forum (Basel, 24th to 26th of October 2019) est apparu en premier sur ETAP-LAB.

Come and meet Syncrosome at #BIO2019 booth #2109.

Syncrosome invites you to visit us at BioConvention, June 3rd to June 7th 2016, in Philadelphia, USA.

Emmanuelle Bettendorf, our Account Manager would be delighted to meet you their and discuss your in vivo preclinical projects.

We can give you advice about our in vivo efficacy, CNS-PK and PK services, discuss any in vitro or in vivo project requirements that you might have or just to get to know each other.

#BIO2019 #SouthOfFranceAtBIO19

L’article Syncrosome will attend the Next BioConvention in Philadelphia, USA est apparu en premier sur ETAP-LAB.

Thanks to its CNS expertise our CNS Study Monitor, Dr. Delphine Revy, will present several results on Symptomatic and biochemical assessment of an antidyskinetic compound in a L-DOPA induced Dyskinesias rat model.

A few words about Syncrosome: 

Syncrosome is an Efficacy Characterization CRO and we offer relevant disease models, cutting-edge techniques and a comprehensive background of physiopathology to assist drug discovery companies.

We have developped and validated so far more than 15 disease models, and our flexible and human-sized organization can design and operate tailored experimental protocols to give you appropriate answers.

Our main activities consit in :

• Drug Efficacy Studiesin several therapeutic areas :
  • Central Nervous Sytem, 
  • Cardiovascular and Metabolic disease, 
  • Respiratory,
  • Gastroenterology.

Early bioavailibility and CNS-PKon rodents and non-rodents with a high competence in the study of the Blood Brain Barrier passage.

L’article Syncrosome at the next NeuroFrance Congress in Marseille est apparu en premier sur ETAP-LAB.

Syncrosome is involved in Central Nervous System activities for 16 years with a specific department dedicated to several CNS disease models, and more specifically Parkinson Disease (PD).

This department is also focused on CNS-PK with relevant tools as microdialysis and CSF sampling.

I am pleased to inform you that Syncrosome will attend the Translational Neuroscience Congress, in Paris, France on January, 25th 2019.

The idea for Syncrosome is to Keep up to date on Parkinsonian animal models and to evaluate the new trend for 2019 and later…

Key topics will be discussed:

• Translational research on neurodegenerative disease
• Imaging & RMN spectroscopy 
• Advances in Animal model

and we’ll have the chance to exchange with Key Biotech and Pharma companies like Lundbeck, Prexton, Amabiotics, Theranexus … and Center of Excellence in Neurodegenerative diseases like DHUNE…

Looking forward to seeing you soon,

Give a look to our website.

Syncrosome team

To schedule a meeting with Syncrosome representatives, please email Emmanuelle Bettendorf, your preferred preclinical CRO contact!

L’article Syncrosome & the Translational Neuroscience Congress est apparu en premier sur ETAP-LAB.

• A new atopic dermatitis model, the DNCB-induced model in Balb/c mice, has been developed with effective studies already in progress.

• New studies for the account of TEMESIS have been performed showing remarkable effects of their lead TEM1657 drug candidate on Psoriasis and results have been presented in different congresses. Different formulations of their product remaining to be characterized.

• Jean-François Bisson participated to the World Preclinical Congress in Lisbon to discuss chronobiology and animal welfare, a key point of our activity. Indeed, ETAP-Lab controls reverse light cycle and behavioral animal tests are run during their activity phases in order to have a thorough follow-up of the animal but also to monitor the possible side effects of a product.

• ETAP-Lab has acquired new equipment including a C-Cube camera allowing to make reproducible pictures in very high quality, which is essential for the follow-up for the development of dermatological diseases.

• ETAP-Lab established a collaboration with the European Institute of Antioxidants to measure total antioxidant capacities in skin tissue and fluids using PAOT^© Technologies. Now, ETAP-Lab can pursue studies on antioxidant compounds administered locally or orally for other dermatological conditions such as vitiligo, extending further research possibilities.

• A metagenomic project for the analysis of bacterial strains at the cutaneous level before (healthy mice) and after pathology induction (psoriasis, atopic dermatitis, skin inflammation) is in progress. 

• Some projects and studies will be launched in 2019, including:

 → A preclinical study aiming at evaluating the efficacy of a miniaturized smart system built up to improve wound healing by light stimulation within the framework, the European project “MEDILIGHT”.

→ A study on skin explant models in animals for severe burns or long-term healing. Building the tests to evaluate explants’ parameters is planned for 2019.

• Several new models are in progress and envisaged for 2019, including:

→ Atopic dermatitis mice model with mite induction, only available in Asia at the present time.

→ Vitiligo, acne, rosacea and alopecia mice models.

Through this year, ETAP-Lab has been able to prosper in the dermatology field with various projects, models and collaborations completed over the world. The main objective in 2019 is to develop new models/study methods to answer customer needs as well as future therapeutic issues. 

We are grateful for the trust that customers have placed in us to design and validate new models, as well as to carry out their pre-clinical studies. We are committed to always provide services of quality, rigor, ethical compliance, reactivity and are delighted to constantly evolve according to customer specific demands.

Annual Report of 2018

L’article Annual Report of 2018 est apparu en premier sur ETAP-LAB.

If you are searching for a reliable partner for in vivo preclinical studies, please contact Jean-François BISSON at: jfbisson@etap-lab.com and you could meet there at the end of November. For more information about the meeting click here.

L’article ETAP-Lab participation at the World Preclinical Congress Europe 2018 in Lisbon est apparu en premier sur ETAP-LAB.

The 6^ThDrug Discovery Innovation Programme will feature 2 days of interactive presentations, poster presentation and networking opportunity, in Frankfurt (Germany) from 29 to 30^thof October. This conference will offer a complete programme focusing on preclinical animal models, breakthrough technologies :

• Target engagement
• Advances in medicinal chemistry
• Pre-clinical pharmacokinetics
• Modern approaches for drug design
• Role of AI in drug discovery
• Open innovation…

Syncrosome is happy to host a booth and participate to the networking event.

Syncrosome provides a complete service in Preclinical Efficacy testing from in vitro to in vivo testing and trough biodisponibility studies on rodents and non-rodents species. Our multiple skills, combined with scientific background and 18 years of expertize results in fruitful collaboration with Pharmaceutical and Biotech. Companies.

For additional information on our conference participation or to schedule a meeting with Emmanuelle Bettendorf, please email us.

L’article Syncrosome will be pleased to meet you at Frankfurt during the 6th DDIP Congress est apparu en premier sur ETAP-LAB.

Researchers from Europe but also from other non-European countries (USA, India, Jordan, Indonesia…) participated to this congress as well. Therefore, most recent advances have been presented concerning the diagnosis and the treatment of several pathologies including wound healing, psoriasis, atopic dermatitis, acne, facial rejuvenation and skin bleaching.

A focus on the use of bioengineered skin for preclinical and clinical applications has also been made by Pr. Marcela Del Rio from the University Carlos III of Madrid.

Bioengineered skin substitutes are effectively used in a preclinical context with skin grafting in immunodeficient mice, not only to classical disease models such as psoriasis but also to address rare genetic skin diseases such as genodermatoses, xeroderma pigmentosum, epidermolysis bulbosa…, and to better understand physiological processes.

In the near future, skin tissue engineering will become a multidisciplinary science with the development of a next generation of biomimic skin substitutes.

L’article 18th Global Dermatology Congress October 25-26, 2018, Budapest, Hungary est apparu en premier sur ETAP-LAB.

Dr. Nicolas VIOLLE will attend to the 3rd European Stroke Organization Conference ​ (ESOC) from 16-18 May, 2017 (Prague).

ESOC is one of the most exiting conference this year about clinical trials and developments in stroke management, treatment and prevention.
It will be the occasion for us to meet leaders from pharmaceutical industry to present STROM@LLIANCE, the new service 100% dedicated to preclinical stroke research.

Contact us from now to schedule a meeting.

L’article Meet us at ESOC 2017 est apparu en premier sur ETAP-LAB.

For more information about this meeting click here.

L’article ETAP-Lab participation to NutrEvent 2017 est apparu en premier sur ETAP-LAB.

L’article ETAP-Lab participation to ESOC 2017 est apparu en premier sur ETAP-LAB.

L’article ETAP-Lab participation to AFSTAL 2017 est apparu en premier sur ETAP-LAB.

Organized in september 2015 in Amsterdam, ERS 2015 European Respiratory Society)  is an international congress on Respiratory diseases, with more than 20 000 attendees! SYNCROSOME was extremely proud to be part of the adventure this year, with a new poster presenting our development on a new  innovative PAH Sugen in vivo model, wich has been accepted at the congress.

Data shows very interesting results concerning several parameters including translationnal biomarkers, histology, hemodynamic and Right Ventricular hypertrophy.

To download the poster:

http://pro.syncrosome.com/941-poster-pah-sugen-ers-2015-syncrosome

L’article Syncrosome: poster Preclinical PAH Sugen – European Respiratory Society meeting est apparu en premier sur ETAP-LAB.

Syncrosome invites you to visit us at Bio-Europe, November 7th to November 9th 2016, in Cologne, Germany.

Emmanuelle Bettendorf, our Business Developer would be delighted to meet you their and discuss your in vivo preclinical projects.

We can give you advice about our in vivo efficacy, CNS-PK and PK services, discuss any in vitro or in vivo project requirements that you might have or just to get to know each other.

Please contact us to organize a 1-2-1 meeting in Cologne!

A few words about Syncrosome:

Syncrosome is an Efficacy Characterization CRO and we offer relevant disease models, cutting-edge techniques and a comprehensive background of physiopathology to assist drug discovery companies.

We have developped and validated so far more than 15 disease models, and our flexible and human-sized organization can design and operate tailored experimental protocols to give you appropriate answers.

Our main activities consit in :

• Drug Efficacy Studies in several therapeutic areas :
  • Central Nervous Sytem,
  • Cardiovascular and Metabolic disease,
  • Respiratory,
  • Gastrointestinal.
• Early bioavailibility and CNS-PK on rodents and non-rodents with a high competence in the study of the Blood Brain Barrier passage.

L’article Join Syncrosome team at Bio-Europe in Cologne, Germany, next week! est apparu en premier sur ETAP-LAB.

Hi Europe &Ni promises you a complete 360 degree perspective of the nutrition and health ingredients industry through an exclusive offering of new ingredients & solutions, innovative tours, presentations & live demonstrations.

We are in Frankfurt from 29 November – 1 December and would like to invite you to our booth!

WE’LL BE WAITING FOR YOU
AT STAND F48-5

We will showcase our latest innovations and our team will be ready to meet you face-to-face..

We look forward to seeing you in Frankfurt!

L’article Join ETAP-Lab at Hi Europe & Ni est apparu en premier sur ETAP-LAB.

Syncrosome is happy to host a booth and participate to the networking event.

Syncrosome provides a complete service in Preclinical Efficacy testing from in vitro to in vivo testing and trough biodisponibility studies on rodents and non-rodents species. Our multiple skills, combined with scientific background and 15 years of expertize results in fruitful collaboration with Pharmaceutical and Biotech. Companies.

Come on our booth and visit us

• Meet Emmanuelle, your Business contact at Syncrosome since 2009
• Discover our new in vitro and vivo models
• Discuss your preclinical project with experts and save time on your project

Looking forward to seeing you soon,

Give a look to our website.

Syncrosome team

To schedule a meeting with Syncrosome representatives, please email Emmanuelle Bettendorf, your preferred preclinical CRO contact!

L’article Syncrosome at the 2nd DDIP in Munich est apparu en premier sur ETAP-LAB.

ETAP-Lab’s preclinical results obtained for PiLeJe will be presented in a poster “Identification of two probiotic strains able to prevent skin inflammation in a murine model” at the 4^th World Congress on Targeting Microbiota, October 17-19, 2016, Institut Pasteur, Paris (France).

Congress Website

PiLeJe Website

L’article Poster presentation at the 4th World Congress on Targeting Microbiota est apparu en premier sur ETAP-LAB.

Syncrosome is involved in Central Nervous System activities for 16 years with a specific department dedicated to several CNS disease models, and more specifically Parkinson Disease (PD).

This department is also focused on CNS-PK with relevant tools as microdialysis and CSF sampling.

I am pleased to inform you that Syncrosome will attend the 2^nd Annual Neuroscience R&D Technologies Conference, in London, UK on September 29 – 30, 2016.

During the congress, Sandra Robelet, Scientific Manager in Syncrosome, will make a speech on “ Preclinical strategy combining in vitro and in vivo models to assess drug efficacy in Neurodegenerative disease”. This conference is scheduled the 29^th of September in the morning.

Hereafter you will find some conference’s topics:

• Target identification & Validation technologies : Human pluripotent stem cells to model and treat Parkinson’s disease…
• Translational imaging : The imaging of Neurodegeneration…
• Neuroinformatics & Computational Neurosciences…
• Advances in Animal models…

Come on our booth and visit us

• Meet our Head of Central Nervous System department
• Discover our new in vitro and vivo models
• Discuss your preclinical project with experts and save time on your project
• Find out why our cutting-edge services might be the solutions for your CNS drug development

Looking forward to seeing you soon,

Give a look to our website.

Syncrosome team

To schedule a meeting with Syncrosome representatives, please email Emmanuelle Bettendorf, your preferred preclinical CRO contact!

L’article Syncrosome & the 2nd Annual Neuroscience Conference. est apparu en premier sur ETAP-LAB.

L’article Syncrosome Poster 6 OHDA Parkinson and dyskinesia est apparu en premier sur ETAP-LAB.

For more information about this meeting click here.

L’article Participation of ETAP-Lab to the FIE 2015 in Paris. est apparu en premier sur ETAP-LAB.

For more information about this meeting click here.

L’article ETAP will participate to BIOFIT 2015 on December 1st & 2nd in Strasbourg (France), represented by Nicolas VIOLLE (CEO) and Jean-François BISSON (Scientific Director) est apparu en premier sur ETAP-LAB.

For more information about this meeting click here.

L’article ETAP will participate to the Health Ingredients Europe and Natural Ingredients 2014 (HIE & NI 2014) meeting on December 2 and 3 in Amsterdam, represented by Jean-François BISSON, Scientific Director of ETAP est apparu en premier sur ETAP-LAB.

You can meet Jean-François BISSON (Scientific Director ETAP and ISCHOM Secretary) for any inquiry about the activities of ETAP and experimental models available for your research.

For more information about this congress click here.

L’article ETAP is co-organizing the First International Congress on Chocolate and Cocoa in Medicine that will be held in Florence (Italy) on September 26 to 27, 2014, represented by Jean-François BISSON est apparu en premier sur ETAP-LAB.

For more information about this congress click here.

L’article ETAP will be present to the VITAFOODS Europe 2014 in Geneva (Switzerland) on May 6 and 7 – represented by Jean-François BISSON (Scientific Director) est apparu en premier sur ETAP-LAB.

For more information about this congress click here.

L’article ETAP will be present at the 20th world congress on Parkinson’s disease and related disorders – represented by C. MULLER est apparu en premier sur ETAP-LAB.